Share on StockTwits

Chimerix (NASDAQ:CMRX) CFO Timothy W. Trost sold 5,000 shares of Chimerix stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $25.13, for a total value of $125,650.00. Following the sale, the chief financial officer now directly owns 629 shares of the company’s stock, valued at approximately $15,807. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on CMRX shares. Analysts at Morgan Stanley cut their price target on shares of Chimerix from $34.00 to $33.00 in a research note on Monday. Separately, analysts at Brean Capital initiated coverage on shares of Chimerix in a research note on Tuesday, July 8th. They set a “buy” rating and a $33.00 price target on the stock. Finally, analysts at Brean Capital initiated coverage on shares of Chimerix in a research note on Monday, June 23rd. They set a “buy” rating and a $33.00 price target on the stock. Four research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $33.25.

Shares of Chimerix (NASDAQ:CMRX) traded up 0.51% on Tuesday, hitting $25.53. The stock had a trading volume of 91,834 shares. Chimerix has a 52 week low of $12.96 and a 52 week high of $27.69. The stock has a 50-day moving average of $22.60 and a 200-day moving average of $21.12. The company’s market cap is $910.6 million.

Chimerix (NASDAQ:CMRX) last released its earnings data on Thursday, August 7th. The company reported ($0.39) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.44) by $0.05. Analysts expect that Chimerix will post $-1.68 EPS for the current fiscal year.

Chimerix, Inc is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.